Mizuho Markets Americas LLC Boosts Holdings in AbbVie Inc. $ABBV

Key Points

• Mizuho Markets Americas LLC dramatically increased its AbbVie stake in the fourth quarter, boosting holdings by 8,056.3% to 120,631 shares worth about $27.6 million.
• AbbVie reported strong quarterly results, with earnings of $2.65 per share and revenue of $15 billion, both above estimates. Revenue rose 12.4% year over year, and analysts now expect full-year EPS of 14.3.
• The company has several positive catalysts, including favorable European regulatory opinions for MAVIRET and Allergan Aesthetics’ Boey, plus encouraging oncology data presented at ASCO 2026. Wall Street remains constructive, with a consensus rating of Moderate Buy and a price target of $253.43.

Mizuho Markets Americas LLC raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 8,056.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 120,631 shares of the company's stock after purchasing an additional 119,152 shares during the quarter. Mizuho Markets Americas LLC's holdings in AbbVie were worth $27,563,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ABBV. Brighton Jones LLC boosted its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock worth $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC boosted its stake in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock worth $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its stake in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock worth $210,685,000 after acquiring an additional 612,702 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Up 0.7%

ABBV opened at $216.02 on Friday. AbbVie Inc. has a twelve month low of $181.71 and a twelve month high of $244.81. The company has a 50-day moving average price of $208.72 and a 200 day moving average price of $219.68. The company has a market cap of $381.66 billion, a PE ratio of 106.41, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company's revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ABBV shares. DZ Bank raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday, April 30th. Canaccord Genuity Group increased their target price on shares of AbbVie from $262.00 to $265.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. UBS Group lowered their target price on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research note on Thursday, February 5th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price on the stock. Finally, Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.